BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1334 related articles for article (PubMed ID: 20034854)

  • 1. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy.
    Josephson CD; Mullis NC; Van Demark C; Hillyer CD
    Transfusion; 2004 Jun; 44(6):805-8. PubMed ID: 15157243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of single donor platelet with low antibody titers for all patients.
    Romphruk AV; Cheunta S; Pakoate L; Kumpeera P; Sripara P; Paupairoj C; Romphruk A
    Transfus Apher Sci; 2012 Apr; 46(2):125-8. PubMed ID: 22365668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonfatal intravascular hemolysis in a pediatric patient after transfusion of a platelet unit with high-titer anti-A.
    Harris SB; Josephson CD; Kost CB; Hillyer CD
    Transfusion; 2007 Aug; 47(8):1412-7. PubMed ID: 17655585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemolytic transfusion reaction in a pediatric patient following transfusion of apheresis platelets.
    Sapatnekar S; Sharma G; Downes KA; Wiersma S; McGrath C; Yomtovían R
    J Clin Apher; 2005 Dec; 20(4):225-9. PubMed ID: 16265630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories.
    Fung MK; Downes KA; Shulman IA
    Arch Pathol Lab Med; 2007 Jun; 131(6):909-16. PubMed ID: 17550318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advancement in the preparation of red cell concentrates and platelet concentrates].
    Inaba S
    Masui; 2011 Jan; 60(1):23-30. PubMed ID: 21348247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions.
    Karafin MS; Blagg L; Tobian AA; King KE; Ness PM; Savage WJ
    Transfusion; 2012 Oct; 52(10):2087-93. PubMed ID: 22339320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABO-mismatched transfusions are not over-represented in febrile non-haemolytic transfusion reactions to platelets.
    Yazer MH; Raval JS; Triulzi DJ; Blumberg N
    Vox Sang; 2012 Feb; 102(2):175-7. PubMed ID: 21781126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apheresis platelet transfusions: does ABO matter?
    Herman JH; King KE
    Transfusion; 2004 Jun; 44(6):802-4. PubMed ID: 15157242
    [No Abstract]   [Full Text] [Related]  

  • 11. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma.
    Berséus O; Boman K; Nessen SC; Westerberg LA
    Transfusion; 2013 Jan; 53 Suppl 1():114S-123S. PubMed ID: 23301963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABO incompatible platelets: risks versus benefit.
    Dunbar NM; Ornstein DL; Dumont LJ
    Curr Opin Hematol; 2012 Nov; 19(6):475-9. PubMed ID: 22914587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-A and anti-B titers in pooled group O platelets are comparable to apheresis platelets.
    Cooling LL; Downs TA; Butch SH; Davenport RD
    Transfusion; 2008 Oct; 48(10):2106-13. PubMed ID: 18631162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low titer group O whole blood in emergency situations.
    Strandenes G; Berséus O; Cap AP; Hervig T; Reade M; Prat N; Sailliol A; Gonzales R; Simon CD; Ness P; Doughty HA; Spinella PC; Kristoffersen EK
    Shock; 2014 May; 41 Suppl 1():70-5. PubMed ID: 24569505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets.
    Mair B; Benson K
    Transfusion; 1998 Jan; 38(1):51-5. PubMed ID: 9482394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
    Schetelig J; Breitschaft A; Kröger N; Zabelina T; Ebell W; Bornhäuser M; Haack A; Ehninger G; Salama A; Siegert W;
    Transfusion; 2005 May; 45(5):779-87. PubMed ID: 15847669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs.
    Julmy F; Ammann RA; Taleghani BM; Fontana S; Hirt A; Leibundgut K
    Transfusion; 2009 Jan; 49(1):21-33. PubMed ID: 18774963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants.
    Mehta P; Ramprakash S; Raghuram CP; Trivedi D; Dhanya R; Agarwal RK; Faulkner L
    Ann Hematol; 2021 Aug; 100(8):2071-2078. PubMed ID: 34148110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-A antibody transfused with non-group-specific platelets. Serological abnormalities.
    Thomas L; Tuscany FL; Wilner GD
    Arch Pathol Lab Med; 1981 Jan; 105(1):52-3. PubMed ID: 6893913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.